ScholarIQanswers from OpenAlex & ORCID
Hak Choy
ResearcherPublications, citations & collaboration network
Hak Choy is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hak Choy have?
ScholarIQindexed works
Hak Choy has 257 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hak Choy have?
ScholarIQcitation count
Hak Choy has 16,953 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hak Choy?
ScholarIQh-index
Hak Choy has an h-index of 61 in OpenAlex.
What is the i10-index of Hak Choy?
ScholarIQi10-index
Hak Choy has an i10-index of 143 in OpenAlex.
What is the OpenAlex record for Hak Choy?
ScholarIQopenalex
The OpenAlex for Hak Choy is on the source record.
What are the most-cited papers on Hak Choy?
ScholarIQmost cited works
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki, Gregory A. Masters, George Blumenschein, Steven E. Schild, Jeffrey A. Bogart, Chen Hu, Kenneth Forster, Anthony M. Magliocco, Vivek S. Kavadi, Yolanda I. Garces, Samir Narayan, Puneeth Iyengar, Clifford G. Robinson, Raymond B. Wynn, Christopher D. Koprowski, Joanne Meng, Jonathan J. Beitler, Rakesh Gaur, Walter J. Curran, Hak Choy
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Steven E. Schild, Jeffrey A. Bogart, Kenneth Forster, Anthony M. Magliocco, Vivek S. Kavadi, Samir Narayan, Puneeth Iyengar, Clifford G. Robinson, Raymond B. Wynn, Christopher D. Koprowski, Michael R. Olson, Joanne Meng, Rebecca Paulus, Walter J. Curran, Hak Choy
Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer
Robert Timmerman, Rebecca Paulus, Harvey I. Pass, Elizabeth Gore, Martin J. Edelman, James M. Galvin, William L. Straube, Lucien Nedzi, Ronald C. McGarry, Clifford G. Robinson, Peter B. Schiff, Garrick C. Chang, Billy W. Loo, Jeffrey D. Bradley, Hak Choy
Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
Glenwood Goss, Chris J. O’Callaghan, Ian Lorimer, Ming‐Sound Tsao, Gregory A. Masters, James R. Jett, Martin J. Edelman, Rogério Lilenbaum, Hak Choy, Fadlo R. Khuri, Katherine M.W. Pisters, David R. Gandara, Kemp H. Kernstine, Charles Butts, Jonathan Noble, Thomas A. Hensing, Kendrith M. Rowland, Joan H. Schiller, Keyue Ding, Frances A. Shepherd